123 related articles for article (PubMed ID: 29242303)
1. Ibrutinib does not affect ristocetin-induced platelet aggregation evaluated by light transmission aggregometry in chronic lymphocytic leukemia patients.
Alberelli MA; Innocenti I; Autore F; Laurenti L; De Candia E
Haematologica; 2018 Mar; 103(3):e119-e122. PubMed ID: 29242303
[No Abstract] [Full Text] [Related]
2. Incidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib.
Lipsky AH; Farooqui MZ; Tian X; Martyr S; Cullinane AM; Nghiem K; Sun C; Valdez J; Niemann CU; Herman SE; Saba N; Soto S; Marti G; Uzel G; Holland SM; Lozier JN; Wiestner A
Haematologica; 2015 Dec; 100(12):1571-8. PubMed ID: 26430171
[TBL] [Abstract][Full Text] [Related]
3. Ristocetin-induced platelet aggregation for monitoring of bleeding tendency in CLL treated with ibrutinib.
Kazianka L; Drucker C; Skrabs C; Thomas W; Melchardt T; Struve S; Bergmann M; Staber PB; Porpaczy E; Einberger C; Heinz M; Hauswirth A; Raderer M; Pabinger I; Thalhammer R; Egle A; Wendtner CM; Follows G; Hoermann G; Quehenberger P; Jilma B; Jaeger U
Leukemia; 2017 May; 31(5):1117-1122. PubMed ID: 27909342
[TBL] [Abstract][Full Text] [Related]
4. Assessment of platelet function with light transmission aggregometry in 24 patients supported with a continuous-flow left ventricular assist device: a single-center experience.
Fiore M; James C; Mouton C; Calderon J; Barandon L; Ouattara A; Picard F
J Thorac Cardiovasc Surg; 2014 Dec; 148(6):3119-25.e1. PubMed ID: 25212058
[TBL] [Abstract][Full Text] [Related]
5. Differences and similarities in the effects of ibrutinib and acalabrutinib on platelet functions.
Series J; Garcia C; Levade M; Viaud J; Sié P; Ysebaert L; Payrastre B
Haematologica; 2019 Nov; 104(11):2292-2299. PubMed ID: 30819914
[TBL] [Abstract][Full Text] [Related]
6. Effects of ibrutinib on in vitro platelet aggregation in blood samples from healthy donors and donors with platelet dysfunction.
Ninomoto J; Mokatrin A; Kinoshita T; Marimpietri C; Barrett TD; Chang BY; Sukbuntherng J; James DF; Crowther M
Hematology; 2020 Dec; 25(1):112-117. PubMed ID: 32131714
[No Abstract] [Full Text] [Related]
7. Does platelet count in platelet-rich plasma influence slope, maximal amplitude and lag phase in healthy individuals? Results of light transmission aggregometry.
Chandrashekar V
Platelets; 2015; 26(7):699-701. PubMed ID: 25902305
[TBL] [Abstract][Full Text] [Related]
8. Comparison of platelet aggregation using light transmission and multiple electrode aggregometry in Glanzmann thrombasthenia.
Awidi A; Maqablah A; Dweik M; Bsoul N; Abu-Khader A
Platelets; 2009 Aug; 20(5):297-301. PubMed ID: 19548178
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of an automated light transmission aggregometry.
Ling LQ; Liao J; Niu Q; Wang X; Jia J; Zuo CH; Jiang H; Zhou J
Platelets; 2017 Nov; 28(7):712-719. PubMed ID: 28150526
[TBL] [Abstract][Full Text] [Related]
10. Ristocetin-Induced Platelet Aggregation (RIPA) and RIPA Mixing Studies.
Frontroth JP; Favaloro EJ
Methods Mol Biol; 2017; 1646():473-494. PubMed ID: 28804849
[TBL] [Abstract][Full Text] [Related]
11. The effectiveness of ibrutinib in chronic lymphocytic leukaemia: a nationwide, population-based study in the Netherlands.
van der Straten L; Levin MD; Visser O; Blijlevens NMA; Cornelissen JJ; Doorduijn JK; Kater AP; Dinmohamed AG
Br J Haematol; 2020 Mar; 188(6):e109-e112. PubMed ID: 31991479
[No Abstract] [Full Text] [Related]
12. Testing agonist-induced platelet aggregation by the Impact-R [Cone and plate(let) analyzer (CPA)].
Shenkman B; Einav Y; Salomon O; Varon D; Savion N
Platelets; 2008 Sep; 19(6):440-6. PubMed ID: 18925512
[TBL] [Abstract][Full Text] [Related]
13. The ibrutinib B-cell proliferation inhibition is potentiated in vitro by dexamethasone: Application to chronic lymphocytic leukemia.
Manzoni D; Catallo R; Chebel A; Baseggio L; Michallet AS; Roualdes O; Magaud JP; Salles G; Ffrench M
Leuk Res; 2016 Aug; 47():1-7. PubMed ID: 27235717
[TBL] [Abstract][Full Text] [Related]
14. Storage pool disease in chronic lymphocytic leukemia: abnormal aggregation and secretion without bleeding.
Carr ME; Hines S; Carr SL; Todd WM; Taylor TL; Mohanty L
Am J Med Sci; 1997 Mar; 313(3):176-81. PubMed ID: 9075435
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and toxicity of compassionate ibrutinib use in relapsed/refractory chronic lymphocytic leukemia in Poland: analysis of the Polish Adult Leukemia Group (PALG).
Iskierka-Jażdżewska E; Hus M; Giannopoulos K; Mądro E; Hołojda J; Piotrowska M; Zaucha JM; Piszczek W; Szeremet A; Wojciechowska M; Steckiewicz P; Knopińska-Posłuszny W; Osowiecki M; Drozd-Sokołowska J; Kumiega B; Kyrcz-Krzemień S; Hałka J; Dudziński M; Wieszczy P; Robak T; Warzocha K; Jamroziak K
Leuk Lymphoma; 2017 Oct; 58(10):2485-2488. PubMed ID: 28278701
[No Abstract] [Full Text] [Related]
16. A new platelet function test.
Ryan WL; Hakenkamp K; Sullivan E
Thromb Res; 1990 Apr; 58(2):163-73. PubMed ID: 2112272
[TBL] [Abstract][Full Text] [Related]
17. Diagnosis of Glanzmann thrombasthenia by whole blood impedance analyzer (MEA) vs. light transmission aggregometry.
Albanyan A; Al-Musa A; AlNounou R; Al Zahrani H; Nasr R; AlJefri A; Saleh M; Malik A; Masmali H; Owaidah T
Int J Lab Hematol; 2015 Aug; 37(4):503-8. PubMed ID: 25537026
[TBL] [Abstract][Full Text] [Related]
18. In vivo effect of losartan on platelet aggregation in patients with hypertension.
Akdemir R; Ozhan H; Yazici M; Gunduz H; Duran S; Gurel C; Ozdas S; Uyan C; Basar I; Ulutin T
Heart Vessels; 2004 Jul; 19(4):167-71. PubMed ID: 15278389
[TBL] [Abstract][Full Text] [Related]
19. The splicing modulator sudemycin induces a specific antitumor response and cooperates with ibrutinib in chronic lymphocytic leukemia.
Xargay-Torrent S; López-Guerra M; Rosich L; Montraveta A; Roldán J; Rodríguez V; Villamor N; Aymerich M; Lagisetti C; Webb TR; López-Otín C; Campo E; Colomer D
Oncotarget; 2015 Sep; 6(26):22734-49. PubMed ID: 26068951
[TBL] [Abstract][Full Text] [Related]
20. Ibrutinib modifies the function of monocyte/macrophage population in chronic lymphocytic leukemia.
Fiorcari S; Maffei R; Audrito V; Martinelli S; Ten Hacken E; Zucchini P; Grisendi G; Potenza L; Luppi M; Burger JA; Deaglio S; Marasca R
Oncotarget; 2016 Oct; 7(40):65968-65981. PubMed ID: 27602755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
